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DNA methylation is an important component of the epigenetic
regulation of gene expression in eukaryotic cells. Methylation of CpG
dinucleotides within transcriptional regulatory sequences often re-
sults in reduced expression or silencing of adjacent genes [1–3]. Global
hypomethylation has been associated with chromosomal instability,
while hypermethylation of the promoters of certain tumor suppressor
genes is an important event in malignant transformation [4–8].
There are three predominant methods for investigating DNA
methylation. The ﬁrstmethod is an antibody-based, afﬁnity puriﬁcation
procedure that captures methylated DNA [9–11]. The secondmethod is
bisulﬁte sequencing, which converts unmethylated cytosines to uracils
that are subsequently recognized as thymines [12,13]. The thirdmethod
makes use of methylation-sensitive restriction enzymes, which only
cleave DNA when their recognition sites are unmethylated [14]. Thesethree approaches can be combined with electrophoresis, tag based
sequencing [15], microarray analysis [9,11,16–21] or high-throughput
sequencing [22–25].
High-throughput sequencing can report the sequence of millions of
DNA fragments in parallel. This technology has revolutionized the
analysis of genome-wide histone modiﬁcations [26] and the re-
sequencing of the human genome [27], as well as the analysis of
transcription start sites (TSSs) [28], full-length RNAs [29], small RNAs
[30], single nucleotide polymorphisms (SNPs) [31], and transcription
factor combination domains [32].
The development of new technology has driven new discoveries in
the area of DNAmethylation. Meissner et al. showed that alterations in
histone modiﬁcation can reduce DNA methylation [22]. Irizarry et al.
demonstrated that most tissue-speciﬁc differentially methylated re-
gions (T-DMRs) and cancer-speciﬁc DMRs (C-DMRs) localize to CpG
island shore regions [21,33]. Moreover, it has been established that DNA
methylation in both the promoter and the gene body can affect gene
expression [11,16,34,35]. Evolutionarily conserved regions (ECRs)
within the gene bodyhave been reported to act as alternative promoters
under the control of DNA methylation [36]. On the other hand, DNA
methylation occurs not only on CpG dinucleotides but also in non-CG
contexts (mCHG and mCHH, where H=A, C or T) in embryonic stem
cells [37].
Each method of methylation detection has its advantages and
limitations. The use of antibodies allows determination of the methyl
cytosine density within a region of interest. The use of methylation-
sensitive restriction enzymes is only useful for the analysis of
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global DNA methylation proﬁle of the genome at the single-base level
requires bisulﬁte sequencing. Whole genome bisulﬁte sequencing has
been accomplished in Arabidopsis and humans by using second
generation sequencing technology [23,24,37]. However, the wide-
spread application of this method is currently limited due to the vast
quantity of data it generates and its huge cost. Here, we report a
simple, low-cost method to detect global DNA methylation, which
combines the use of methylation-sensitive restriction enzymes
together with second generation sequencing technology.2. Methods
2.1. Cell culture and sample preparation
Tumor samples examined in the present study comprised colon
cancer cell lines HT29 and HCT116 obtained from the ATCC. Cells were
cultured in McCoy's 5A medium supplemented with 10% fetal bovine
serum. Genomic DNA was isolated using a QIAamp DNA mini kit
(QIAGEN) according to the manufacturer's protocol.2.2. Generation ofmethylation-speciﬁc digital sequencing (MSDS) libraries
Genomic DNA (1 μg) was digested sequentially with the
methylation-sensitive enzymes, SacII, EagI and BssHII (Table 1).
DNA was ﬁrst digested by SacII (NEB) at 37 °C for 3 h, then by EagI
(NEB) at 37 °C for 3 h, and ﬁnally by BssHII (NEB) at 50 °C for 3 h.
Digested sampleswere then puriﬁed by phenol-chloroform extraction
and the fragments were ligated to biotinylated linkers containing
synthetic restriction sites using T4 DNA ligase (Invitrogen), as follows:
(BssHII-A, 5′-bio-CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGT-
GATG-3′, BssHII-B, 5′-pho-CGCGCATCACCGACTGCCCATAGAGAG-
G A A A G C G G A G G C G T A G T G G T T - 3 ′ , E a g I - A , 5 ′ - b i o -
CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGATC-3′, EagI-B,
5′-pho-GGCCGATCACCGACTGCCCATAGAGAGGAAAGCGGAGGCG-
TAGTGGTT-3′, SacII-A, 5′-bio-CCACTACGCCTCCGCTTTCCTCTC-
T A T G G G C A G T C G G T G A T C C G C - 3 ′ , S a c I I - B , 5 ′ - p h o -
GGATCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTGGTT-3′).
The ligated DNA was then fragmented randomly using an ultrasonic
device and 110–160 bp fragments were isolated by PAGE. Non-
methylated ends were enriched using streptavidin beads. The ends
of the DNA were repaired using the End-it DNA End repair kit
(Epicentre) so that they were blunt-ended. Repaired fragments were
then ligated to the following blunt-ended linkers using T4 DNA ligase:
(blunt-linker-A, 5′-CTGCCCCGGGTTCCTCATTCTCT-3′, blunt-linker-B,
5′-AGAGAATGAGGAACCCGGGGCAGTT-3′). The ligated DNA was am-
pliﬁed by PCR using linker-speciﬁc primers (primer-A, 5′-CCAC-
TACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGAT-3′, primer-B, 5′-Table 1
The number of restriction sites for the methylation-sensitive enzymes BssHII, EagI and SacI
Enzyme Recognition site No. of total sites in
human genome
BssHII G^CGCGC 6 bp 72,899
EagI C^GGCCG 6 bp 90,190
SacII CCGC^GG 6 bp 66,312
BssHII+EagI+SacII 229,401
Deﬁned site data
No. of deﬁned sites within
human genome
No. of genes containing the
site within the promoter re
MSDS method 86,897 11,217
Promoter region is deﬁned as the region 500 bp either side of the TSS.CTGCCCCGGGTTCCTCATTCTCT-3′) and sequenced in 35 bp reads on
the Life Technologies’ SOLiD sequencer (Fig. 1A).
2.3. Data analysis
Sequencing data (30/35 bp per sequencing read) was analyzed
using Corona Light software. Human genome sequence and mapping
information (Mar. 2006, hg18) was downloaded from the University
of California Santa Cruz Genome Bioinformatics Site and used to
construct a virtual BssHII, EagI and SacII tag library on the basis of the
genome sequence. Genes neighboring each restriction enzyme site
were also identiﬁed in order to determine the effect of methylation on
their expression.
Each enzyme site contributes two tags to the sequence library: a
plus-strand library tag and a minus-strand library tag. The methylation
level of an enzyme site can be inferred by either of the two sequence tag
counts;we selected the tag that generated thegreaternumber of counts.
When the distance between two successive restriction enzyme sites is
less than about 100 bp, the tags cannot be sequenced, because the tags
are deleted by the PAGE selection. CpGs localized in close proximity to
one another are often co-methylated [37], such that the level of
methylation of one enzyme site can usually be inferred from the level of
methylation of other sites localized within the same area, when the
distance between sites is too small. In situations where the distance
between these enzymes sites was b100 bp, the sites were considered
together as a group, and we again selected the tag that generated the
greatest number of counts within the group. If the tag sequence
matched a site within a repeated sequence or at more than two sites
within thewhole human genome, the tagwas excluded. Excluding such
sequences, 86,897 sites were analyzed (Table 1).
2.4. Bisulﬁte sequencing
Bisulﬁte modiﬁcation of genomic DNA was performed using the
EpiTect Bisulﬁte Kit (Qiagen). Primers were designed using Methyl
Primer Express software (Life Technologies). Bisulﬁte-treated DNA was
ampliﬁed by PCR. The PCR products were cloned into the pCR2.1-TOPO
Vector, then transformed into One Shot TOP10 Competent Cells
(Invitrogen). At least 24 clones were sequenced using an ABI3730
Sequencer (Life Technologies). The data was analyzed using the
Quantiﬁcation Tool for Methylation Analysis (Riken Institute of Physical
and Chemical Research).
2.5. Gene expression data
Gene expression data for theHT29 cellswas generated as described
previously [28], while for the HCT116 cells, this data was obtained
using 5'SOLiD technology [28]. Analysis of gene expression data was
based on the 5′ SOLiD method [28].I, in silico data.
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Fig. 1. Flowchart schematicof themethylation-speciﬁc digital sequencing(MSDS)methodand the correlationbetweenmethylation level as assessedbybisulﬁte sequencingand theMSDS
methylation tag count. A.GenomicDNAwas digestedwithmethylation-sensitive restriction enzymes and ligated tobiotinylated linkers. The ligated samplewas then cleaved by sonication
and the fragmentswere capturedwith streptavidin beads. The capturedDNA fragmentswere ligated to blunt-end linkers, ampliﬁedby PCR, and sequenced on the Life Technologies’ SOLiD
sequencer. B. Scatter diagram ofMSDS tag counts corresponding to 100 regions selected at random thatwere also subjected to bisulﬁte sequencing. Sample labels a–d and e-j indicate sets
of genes whose pattern of methylation was similar (a–d) or different (e–j) between HT29 and HCT116 cells. C. DNA methylation of genes a-j as analyzed by bisulﬁte sequencing. Gray
squares represent CpG sites within restriction enzyme sites. Circles represent potential methylation sites (CpG) where the shading intensity indicates the frequency at which the site was
found to bemethylated amongst the clones analyzed (0–100%). a. TNFRSF8 (tumor necrosis factor receptor superfamily, member 8) gene promoter; b. CXCL5 (chemokine (C–X–Cmotif)
ligand 5) gene promoter; c. SNX14 (sorting nexin 14) gene promoter; d. intergenic region within CpG island; e. NKAIN3 (Na+/K+ transporting ATPase interacting 3) gene; f. GJC1 (gap
junctionprotein, gamma1, 45kDa) genepromoter; g.NPHS1 (nephrosis 1, congenital, Finnish type (nephrin)) geneexon; h.CD47 (CD47molecule)genepromoter; i. B7H6(B7homolog6)
gene intron; j. intergenic region within CpG island. D. and E. Correlation between methylation level as assessed by bisulﬁte sequencing and methylation tag count as assessed by MSDS.
Horizontal bars represent methylation as determined by bisulﬁte sequencing. In E, boxes represent the quartiles and whiskers mark the 5th and 95th percentiles.
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3.1. MSDS analysis
We have developed a simple method, which we call MSDS, to
detect global DNA methylation. The method makes use of threemethylation-sensitive restriction enzymes (BssHII, EagI, and SacII)
and second generation sequencing technology. There are two CpG
dinucleotides within the recognition sequence of each enzyme
(GCGCGC, CGGCCG, and CCGCGG, respectively). Short sequence tag
fragments derived from the sites cleaved by these restriction
enzymes can be mapped to unique sites within the genome. In silico
Table 3
Level of DNA methylation at CpG sites in HT29 and HCT116 cells.
Methylation level No. of CpG sites
HT29 % HCT116 %
Low 27,478 31.60% 25,240 29.00%
Middle 10,112 11.60% 5485 6.30%
High 49,307 56.70% 56,172 64.60%
0 tag count sites 35,309 40.63% 48,141 55.40%
Total CpG sites 86,897 100% 86,897 100%
Low level corresponds to 0–20% methylation, by bisulﬁte sequencing analysis, and
corresponds to a tag count of greater than 16, whereas the high level corresponds to
80%~methylation and is correlated with tag counts between zero and ﬁve.
283K. Ogoshi et al. / Genomics 98 (2011) 280–287analyses indicate that there are 72,899, 90,190 and 66,312
recognition sites for BssHII, EagI and SacII within the human genome,
respectively (Table 1). These restriction sites cover 64% (13,978) of
unique gene promoters (within 500 bp of the TSS) and 75% (21,164)
of the CpG islands within the genome. This combination of
restriction enzymes allowed the most comprehensive coverage of
CpG islands without using a greater number of enzymes. After
excluding certain uninformative sites as described in Section 2.3, we
analyzed a total of 86,897 sites. These deﬁned sites cover 51%
(11,217) of unique gene promoters (Supplemental Table 1), 69%
(19,592) of CpG islands, and 8522 CpG island shores within the
genome (Table 1).
Two colon cancer cell lines (HT29 and HCT116) were utilized to
conﬁrm the utility of thismethod. Using the SOLiD platform, 2,397,132
and 2,971,226 tags were mapped to the human genome in HT29 and
HCT116 cells, respectively. After excluding uninformative sites as
noted above, 1,493,950 tags (62.3% of total tags) in HT29 cells and
1,886,310 tags (63.5% of total tags) in HCT116 cells were matched to
the remaining informative sites (Table 2, Supplementary Fig. 1). There
were 35,309 (40.6%), and 48,141 (55.4%) zero tag count or un-hit sites
in HT29 and HCT116 cells, respectively (Table 3).3.2. Correlation between methylation level (bisulﬁte sequencing) and
MSDS tag counts
To validate the accuracy of the MSDS method, MSDS tag counts
were compared with the results of direct DNA methylation analysis,
which were generated by bisulﬁte sequencing at more than 100
random CpG sites (Fig. 1B). In both cell lines, CpG sites that generated
the highest number of tags corresponded to those that also exhibited a
low level ofmethylation by bisulﬁte sequencing analysis, such as those
within the SNX14 (sorting nexin 14) gene promoter. CpG sites that
generated relatively fewer tags in both cell lines corresponded to those
thatwere highlymethylated in both cell lines according to the bisulﬁte
sequence analysis, such as those within the TNFRSF8 (tumor necrosis
factor receptor superfamily, member 8) gene promoter. Some sites
appeared to be differentially methylated between the two cell lines.
CpG sites that gave rise to many tags in HT29 cells alone were poorly
methylated only in these cells, such as those within the promoter of
the CD47 (CD47 molecule) gene. Similarly, CpG sites that gave rise to
many tags in HCT116 cells alonewere poorlymethylated only in these
cells, such as those within the promoter of the NKAIN3 (Na+/K+
transporting ATPase interacting 3) gene (Fig. 1C). Thus, the methyl-
ation levels determined by bisulﬁte sequencing correlated inversely
with the MSDS tag count in both cell lines. Based on these results
(Fig. 1D), we classiﬁed the genes into three arbitrary groups, based on
the number of tag counts at each restriction enzyme site. Sites
represented by ≥16 tags were considered to be poorly methylated
(b20% methylated), whereas sites represented by ≤5 tags were
considered to be highly methylated (N80% methylated), and sites
represented by 6–15 tags were considered to be methylated at an
intermediate level (21–79% methylated) (Fig. 1E).Table 2
Summary of the results of sequence analysis for methylation tags, MSDS data.
Enzyme No. of tags mapped to the human
genome (% of total tags)
No. of deﬁned tags
HT29 HCT116 HT29 HCT116
BssHII 648,117 (27.0%) 889,793 (29.9%) 415,643 563,851
EagI 1,077,327 (44.9%) 1,141,883 (38.4%) 660,181 740,139
SacII 671,688 (28.0%) 939,550 (31.6%) 418,126 582,320
BssHII+EagI+SacII 2,397,132 2,971,226 1,493,950 1,886,3103.3. Genome-wide DNA methylation
The results of the genome-wide DNA methylation analysis are
presented in Table 3. 56.7% (49,307) and 64.6% (56,172) of unique CpG
sites were highly methylated, and 31.6% (27,478) and 29.0% (25,240)
were poorly methylated in HT29 and HCT116 cells, respectively,
indicating that a majority of CpG sites were either highly or poorly
methylated, which is consistent with what has been reported
previously [37,38]. As CpGs in close proximity are often co-methylated
[37], we considered the tag with the greatest number of counts within
such promoter regions as representative of the methylation level of
those regions. Some gene promoters overlap CpG islands, whereas
others do not. 48% of the promoters evaluated in both cell lines were
poorly methylated (Fig. 2B-1); those that did not overlap CpG islands
were methylated to a greater extent than those that contained a CpG
island within the promoter region (Pb0.01) (Figs. 2B-2, 3). Within
gene body regions, 63% of enzyme sites were highly methylated in
both cell lines (Figs. 2C-1) and the methylation level of CpG islands in
such regions was lower than in other regions of the gene body
(Pb0.01) (Figs. 2C-2, 3). In promoter and gene body, the extent of
methylationwithin CpG islandswas lower than that in regions outside
of the CpG islands (Pb0.01). In addition, there was a difference in the
extent of methylation between CpG islands within the promoter and
CpG islands within the gene body. Methylationwithin CpG islands has
previously been reported to be dependent upon the position of the
island within the promoter region or within the gene body [36].
3.4. Comparison of MSDS methylation with gene expression
There is a strong relationship between gene expression and DNA
methylation. Therefore, we analyzed gene expression in the HT29 and
HCT116 cell lines and compared the results to themethylationdata from
the same cell lines. The genes were divided into three groups: high
expression (≥100 copies), low expression (≤1 copy), and moderate
expression (1bcopies b100) [28]; and the level of expression of the
genes within these groups was compared to the level of methylation.
Highly and moderately expressed genes exhibited a low level of
methylationwithin the promoter and a high level ofmethylationwithin
the gene body. Genes with a low expression level exhibited a moderate
level of methylation within both the gene promoter and the gene body.
These results are consistent with those of previous reports [35,36]
(Fig. 3).
3.5. Differentially methylated regions between HT29 and HCT116
Next, we compared the extent of methylation of the HT29 and
HCT116 cells. Of the sites measured, 77% were methylated to a similar
extent in the two cell lines: 52% of the sites measured were poorly
methylated, and 23% of the sites measured were highly methylated
(Figs. 2A-1). DMRs between the two cell lines were deﬁned as enzyme
sites that were highly methylated in one cell line and poorly
methylated in the other cell line. Such sites made up 9% of the sites
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285K. Ogoshi et al. / Genomics 98 (2011) 280–287measured. Two percent of the sites measured were highly methylated
in HT29 cells and poorly methylated in HCT116 cells, while 7% of the
sites measured were highly methylated in HCT116 cells and poorly
methylated in HT29 cells. As shown in Table 4, many DMRs were
observed not in the gene promoter region, but instead in the gene
body, intergenic or CpG island shore regions.
Finally, we investigated the correlation between the extent of
methylation in the vicinity of the TSS and the expression of the
associated gene.We evaluated the expression of several genes localized
to DMRs within 1000 bp of the TSS and whose expression level differed
at least ﬁve-fold between HT29 and HCT116 cells. Of these genes, we
analyzed those linked to carcinogenesis. These included SMPD3
(sphingomyelin phosphodiesterase 3, neutral membrane (neutral
sphingomyelinase II)), VASH1 (vasohibin 1), and TACC1 (transforming
acidic coiled-coil containing protein 1), which are involved in the cell
cycle; RIPK3 (receptor-interacting serine-threonine kinase 3), and
TNFSF9 (tumor necrosis factor (ligand) superfamily, member 9),
which are involved in apoptosis; and CLDN1 (claudin 1), NELL1 (NEL-
like 1 (chicken)), ROBO1 (roundabout, axon guidance receptor,
homolog 1 (Drosophila)), ENG (endoglin), PLEKHC1 (pleckstrin
homology domain containing, family C) (FERMT2 (fermitin family
member 2)), which are involved in cell adhesion. In these genes, the
DMRs localize to several positions within the gene, in some cases only
upstream of the TSS (e.g. VASH1 and TACC1); in some cases only
downstream of the TSS (e.g. SMPD3, RIPL3, TNFSF9, CLDN1, NELL1 and
ENG); and in some cases, both upstream and downstream of the TSS
(e.g. ROBO1 and PLEKHC1 (FERMT2)) (Fig. 4). In TNFSF9, NELL1 and
ENGgenes, CpG sites closer to the TSS than theDMRweremethylated to
a similar level in both cell lines (Fig. 4). This result demonstrates that
these DMRs are not localized solely in the vicinity of the TSS.
4. Discussion
Diverse methods for the measurement of DNA methylation have
been developed [9,11,16–24]. Moreover, second generation sequenc-
ing technology has facilitated genome-wide analyses of DNA methyl-
ation. However, this technology generates too much data and is too
expensive to be accessible to most researchers in the ﬁeld. Therefore,
we have developed a method for detecting global DNA methylation
that makes use of methylation-sensitive restriction enzymes com-
bined with second generation sequencing technology. The methyla-
tion level can be determined by monitoring the number of times a
particular recognition site is sequenced within the genomic pool. This
method optimizes data handling by limiting the data generated to only
the restriction enzyme sites.Table 4
Differentially methylated regions between the HT29 and HCT116 cell lines.
Gene position No. of sites in each
gene position
No. of differentially
methylated sites
P value
Tags mapped to genome 86,897 7903
CpG island 46,985 3682 1.67E−44
CpG island shorea 9895 1219 2.12E−32
Other region 30,017 3002 1.47E−11
Gene body
−5000~2001 bp 2216 240 0.00399
−2000~1001 bp 1642 187 0.001
−1000~501 bp 2503 264 0.01
−500~1 bp 9178 605 1.16E−18
TSS±50 bp 3562 187 3.65E−16
1st exon 9168 651 2.21E−12
Intron 23,164 2111 0.908
Exon 4191 314 0.0002172
Last exon 2090 180 0.437
Intergenic 32,730 3348 1.55E−19
a CpG island shore; 2000 bp within CpG island.Changes in DNA methylation proﬁles have been observed during
normal development and tumorigenesis. However, differences in the
genome-wide methylation pattern between related cancer cell lines
derived from related tumors have not been examined previously. We
found many sites, localized predominantly to CpG island shore and
intergenic regions, which are differentially methylated in HT29 and
HCT116 cells. Differences between theHT29 andHCT116 cell linesmay
have arisen in the process of transforming fromnormal tissue to cancer
tissue, or may be due to differences in the cells before they became
cancerous. Regions of the genome that are differentially methylated
may provide insight into the variety of regions of the genome where
differential gene expression is linked to the development of cancer. By
searching regions of the genome that are differentially methylated
between cell lines from similar tissue, it may be possible to reveal
differences in the initiation of cancer and/or in the types of cells that
cause the malignant transformation: from a basal cell or layer cell, for
example.
The following genes have been reported to exhibit tumor suppressor
activity and to be regulated by methylation within their promoter
regions: SMPD3 [39], VASH1 [40], RIPK3 [41], TNFSF9 [42], NELL1
[43,44], ROBO1 [45–47], ENG [43,48]. In this study, we identiﬁed
additional genes characterized by a link between DNAmethylation and
expression: TACC1, CLDN1, and PLEKHC1 (FERMT2). These genes may
also be important in carcinogenesis.
Analysis of DNA methylation using microarrays suffers from a bias
towards gene promoter regions and CpG islands. The microarray
method can only provide relative data, and therefore requires a
reference standard. Methods based on restriction enzymes possess
inferior sensitivity to bisulﬁte sequencing, but do allow a quantitative
comparison of methylation patterns. Bisulﬁte sequencing allows
analysis of DNA methylation at the single nucleotide level, but at a
very high cost for a genome the size of the human genome [37].
Established methods that make use of methylation-sensitive
restriction enzymes include methylation-speciﬁc digital karyotyping
(MSDK) [15], modiﬁed methylation-speciﬁc digital karyotyping
(MMSDK) [25], methyl-sensitive cut counting (MSCC) [35] and others.
The MMSDK method is similar to the MSDS method that we have
developed. Bothmethods are based on digital karyotyping technology.
The process of digestion of genomic DNAwith amethylation-sensitive
restriction enzyme, and the use of a fragmenting enzyme with which
to generate short sequence tags is essential to both methods. The key
difference between MSDS and MMSDK is the location of the short
sequence read using second generation sequencing technology. The
MMSDK method targets the nearest NlaIII sites to the methylation-
sensitive enzymes, while the MSDS method targets the methylation-
sensitive enzyme sites themselves. This difference simpliﬁes the
construct preparation process. It results in a shortening of the duration
of the procedure and reduces loss of the sample. Furthermore, it
requires less PCR cycles, and thereforeminimizes PCR bias. During data
analysis, the directly identiﬁable measurement positions make it easy
to perform direct sequencing of the cleavage site. However, because
direct sequencing is employed, when a restriction enzyme site exists
within a repeated sequence, these tags are considered unreliable and
excluded. Accordingly, MSDS method is not able to measure repeated
sequences. The difference between MSCC and MSDS is the combina-
tion of methylation-sensitive enzymes used. MSCC uses the HpaII
enzyme, while MSDS uses three enzymes (BssHII, EagI and SacII).
Methods that make use of methylation-sensitive restriction enzymes
are limited to proﬁling the methylation of these enzyme's recognition
sites, suggesting that use of enzymes that cleave at a greater number of
sites is advantageous. The HpaII and MspI enzymes are four base
encoding enzymes, and the recognition site of each enzyme contains
one CpG dinucleotide within an identical recognition sequence, CCGG.
HpaII cleaves only at unmethylated sites, whereas MspI cleaves both
methylated and unmethylated sites. In silico analyses reveal that there
are approximately two million recognition sites for these enzymes
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Fig. 4. Correlation between the extent of methylation within DMRs and the level of expression of the associated gene. We selected ﬁve genes containing DMRs in close proximity to
the TSSs: TACC1, TNFSF9, CLDN1, NELL1, and PLEKHC1 (FERMT2). The panel to the left shows relative MSDS tag counts (circles) at the relevant sites within each gene in each cell line.
A black box around the two circles represents the position of the DMRs that were selected. The panel on the right shows the relative expression of each gene in each cell line.
286 K. Ogoshi et al. / Genomics 98 (2011) 280–287within the human genome. The MSDS method reported here makes
data analysis simpler because it results in analysis of fewer sites and
therefore fewer tags.
Within the data obtained via the MSDS methods, zero tag count or
un-hit sites made up about 40–50% of the uninformative sites. These
sites may be fully methylated or just false negative. The use of enzymes
that recognize six-base target sequences obviates the need for a
comparison target, as is the case when evaluating MspI against HpaII.
To verify this, we performed bisulﬁte sequencing at 44 CpG sites that
gave rise to a MSDS tag count of zero. We found that 41 of the 44 sites
werehighlymethylated. Thisﬁnding suggests that the bias due to PCRor
cleavage efﬁciency of the restriction enzymes was small, and that the
number of sequence tag countswas enough to cover the total restriction
enzymesites.At the sametime, this false negative rate is considered low.
Under the MSDS method, we determined the cut-off values for poorly,
moderately and highlymethylated sites, based on the results of bisulﬁte
sequencing. The depth of the MSDS sequence affects the cut-off values,
and deeper sequencing coverage should improve accuracy, as is the case
with theMSCCmethod [35]. Quantitative informationwas based on the
comparison between bisulﬁte sequencing data and MSDS tag counts inFig. 1E. The reliability of these data might be affected by imperfect
cleavage by BssHII, EagI and SacII enzymes or a bias derived from the
PCRampliﬁcationused inMSDS.However, the cutting efﬁciency of these
enzymes was veriﬁed, and only a limited number of PCR cycles were
used to make the construct.
The MSDS method was able to detect the difference between highly
methylated and poorly methylated sites. In the process of the
carcinogenesis, DNA methylation is changed in many ways. MSDS was
unable to detectminor changes (10–20%) inDNAmethylation. However,
the MSDS method was able to detect large changes in DNAmethylation
(e.g. a change from 0–20% methylation to 80–100% methylation).
The MSDS method is a robust means of detecting global DNA
methylation. This method has the potential to provide novel insight
into the functional complexity of the human genome, and may also
serve as a basis for the diagnosis of diseases such as cancer.
5. Accession number
MSDS tags have been deposited in the NCBI Short Read Archive
under the project accession SRA028119. Expression tags for HT29 and
287K. Ogoshi et al. / Genomics 98 (2011) 280–287HCT116 cell lines have been deposited in NCBI Short Read Archive
under the project accessions SRA002659 and SRA028119, respectively.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ygeno.2011.07.003.
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